Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16593852 | 0.84 | HDAC6 (0.33) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL12743275 | 0.84 | BTN3A1 (0.32) | — | |
| SCHEMBL28299936 | 0.83 | ALDH1A1 (0.34) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL28423234 | 0.81 | HDAC6 (0.32) | HDAC6HDAC1HDAC2ELANE | |
| SCHEMBL31364246 | 0.79 | HDAC6 (0.35) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL28346522 | 0.79 | PAM (0.36) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL28299938 | 0.78 | ALDH1A1 (0.35) | HDAC6HDAC1HDAC2DGAT1APLNR | |
| SCHEMBL24710351 | 0.77 | HDAC6 (0.33) | HDAC6HDAC1HDAC2 | |
| SCHEMBL314306 | 0.76 | HDAC6 (0.36) | HDAC6HDAC1HDAC2ELANEDGAT1 | |
| SCHEMBL30906709 | 0.76 | CA12 (0.41) | HDAC6HDAC1HDAC2ELANEDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376041-A1 | METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-11-14 | — | — | US | disclosed |
| US-12098115-B2 | Methods and compositions for terpenoid synthesis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-11952327-B2 | Methods and compositions for terpenoid synthesis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240025843-A1 | METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2018053322-A1 | METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-7910558-B2 | therapy for gramnegative bacteria; antibiotics | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910558-B2 | therapy for gramnegative bacteria; antibiotics | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100074863-A1 | ANTI-INFECTIVE PYRROLIDINE DERIVATIVES AND ANALOGS | ENANTA PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20090326019-A1 | 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060252713-A1 | Spirocyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006119384-A1 | SPIROCYCLIC BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060148731-A1 | 11,12-Lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-20060142215-A1 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006065721-A2 | 11, 12-LACTONE BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065743-A2 | TETRACYLIC BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006063039-A2 | 3, 6-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122128-A1 | 3,6-Bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252713-A1 | Spirocyclic bicyclolides | ABCB11, GGPS1, AKR1C3 | HDAC6 163/4885HDAC1 284/4885HDAC2 164/4885 |
| US-20060122128-A1 | 3,6-Bicyclolides | ABCB11, CYP2B6, CYP3A7 | HDAC6 354/4885HDAC1 1200/4885HDAC2 560/4885 |
| US-20090326019-A1 | 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS | ZC3HAV1, EIF2AK2, POLRMT | HDAC6 191/4885HDAC1 291/4885HDAC2 429/4885 |
| US-11952327-B2 | Methods and compositions for terpenoid synthesis | SQLE, GGPS1, LSS | HDAC6 4705/4885HDAC1 4717/4885HDAC2 4661/4885 |
| US-20240376041-A1 | METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESIS | SQLE, GGPS1, LSS | HDAC6 4705/4885HDAC1 4717/4885HDAC2 4661/4885 |
| US-20060142215-A1 | Tetracyclic bicyclolides | ABCB11, CYP7A1, CYP51A1 | HDAC6 210/4885HDAC1 520/4885HDAC2 370/4885 |
| US-20240025843-A1 | METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESIS | SQLE, GGPS1, LSS | HDAC6 4705/4885HDAC1 4717/4885HDAC2 4661/4885 |
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | HDAC6 354/4885HDAC1 1200/4885HDAC2 560/4885 |
| US-20100074863-A1 | ANTI-INFECTIVE PYRROLIDINE DERIVATIVES AND ANALOGS | ZC3HAV1, POLRMT, EIF2AK2 | HDAC6 124/4885HDAC1 317/4885HDAC2 1092/4885 |
| US-20060148731-A1 | 11,12-Lactone bicyclolides | CYP51A1, ABCB11, CYP4A11 | HDAC6 183/4885HDAC1 325/4885HDAC2 315/4885 |
| US-12098115-B2 | Methods and compositions for terpenoid synthesis | SQLE, GGPS1, LSS | HDAC6 4705/4885HDAC1 4717/4885HDAC2 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.